Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Pasritamig

Phase 3Biologic

Johnson & Johnson

Pasritamig is one of 30 biologic programs targeting Prostate Cancer. It is currently in Phase 3.

1

Indications

6

Total Trials

6

Active Trials

29

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerNot yet recruiting

Prostate CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

312 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Androgen Deprivation Therapy

Johnson & Johnson

Acetylsalicylic Acid

GM-CSF

YY-mAbs Therapeutics

Androgen Deprivation Treatment

MMedical University of Vienna

SHR3680

JJiangsu HengRui Medicine Co., Ltd.

Pasritamig

Johnson & Johnson

Trexall

Jazz Pharmaceuticals

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Duragesic

Ranexa

MMenarini International Operations Luxembourg SA

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Prostatic Neoplasms

NCT07319871

Q2 2028

Phase 1Recruiting

Metastatic Castration-Resistant Prostate Neoplasms

NCT05818683

Q3 2028

Phase 3Recruiting

Prostatic Neoplasms

NCT07164443

Q4 2028

Phase 1Not yet recruiting

Prostate Cancer

NCT07860255

Clinical

Trials by Indication[1]

Prostatic Neoplasms2 trials

A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT07319871·40 enrolled

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Engaging Agent Targeting Human Kallikrein 2, With or Without JNJ-87189401, a PSMA-CD28 Costimulatory Agent, Plus Best Supportive Care Versus Best Supportive Care for Late-line Metastatic Castration-resistant Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT07164443·1,203 enrolled

Metastatic Castration-resistant Prostate Neoplasms1 trial

A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05818683·300 enrolled

Prostatic Neoplasms, Castration-Resistant1 trial

A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT07225946·800 enrolled

Metastatic Castration-resistant Prostate Cancer, mCRPC1 trial

A Phase 1b/2, Open-label, Multi-center Study to Evaluate the Anti-cancer Activity, Safety and Tolerability of GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig [T-CELL-Redirecting Agent Targeting Human Kallikrein 2 (KLK2)] in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Progressed on Previous Novel Hormonal Therapy (NHT) (JET-201)

Recruiting·GGI Innovation, Inc.·Preclinical·NCT07871435·107 enrolled

Prostate Cancer1 trial

A Neoadjuvant Trial of Pasritamig in Unfavorable Intermediate to Very High-Risk Localized Prostate Cancer

Not yet recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT07860255·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Pasritamig. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pasritamig compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pasritamig. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Related News